Immune Design Corp. Company Profile (NASDAQ:IMDZ)

About Immune Design Corp.

Immune Design Corp. logoImmune Design Corp. is a clinical stage immunotherapy company. The Company focuses on cancer with in vivo approaches designed to enable the body's immune system to fight disease. The Company is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo. The ZVex vector is a delivery system based on a hybrid, re-engineered virus designed to carry the genetic information of selected tumor antigen in whole or selected epitopes selectively to dendritic cells (DCs) in the skin. When injected into a cancer patient, a ZVex-based product candidate is designed to interact only with these DCs, delivering the tumor antigen in the form of ribonucleic acid (RNA). GLA Adjuvant Systems (GLAAS) is a discovery platform that works in vivo and is based on a synthetic molecule called glucopyranosyl lipid A (GLA).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: IMDZ
  • CUSIP:
Key Metrics:
  • Previous Close: $5.50
  • 50 Day Moving Average: $5.61
  • 200 Day Moving Average: $6.81
  • 52-Week Range: $25,409,000.00 - $4.50
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.15
  • P/E Growth: -0.47
  • Market Cap: $139.75M
  • Outstanding Shares: 25,409,000
  • Beta: 3.01
Profitability:
  • Net Margins: -415.05%
  • Return on Equity: -50.92%
  • Return on Assets: -46.08%
Debt:
  • Current Ratio: 7.33%
  • Quick Ratio: 7.29%
Additional Links:
Companies Related to Immune Design Corp.:

Analyst Ratings

Consensus Ratings for Immune Design Corp. (NASDAQ:IMDZ) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $15.00 (172.73% upside)

Analysts' Ratings History for Immune Design Corp. (NASDAQ:IMDZ)
Show:
DateFirmActionRatingPrice TargetDetails
11/13/2016Cowen and CompanyReiterated RatingBuyView Rating Details
11/10/2016Jefferies Group LLCLower Price TargetBuy$17.00 -> $15.00View Rating Details
6/10/2016Leerink SwannReiterated RatingBuyView Rating Details
5/11/2016Wells Fargo & CompanyReiterated RatingBuyView Rating Details
(Data available from 2/20/2015 forward)

Earnings

Earnings History for Immune Design Corp. (NASDAQ:IMDZ)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/8/2017        
11/9/2016Q316($0.71)($0.60)$1.73 million$8.20 millionViewListenView Earnings Details
5/10/2016Q1($0.62)($0.61)ViewListenView Earnings Details
3/10/2016Q4($0.54)($0.60)$1.06 million$1.10 millionViewListenView Earnings Details
11/12/2015Q315($0.39)($0.37)$4.10 million$4.70 millionViewListenView Earnings Details
8/12/2015Q215($0.47)($0.54)$1.71 millionViewListenView Earnings Details
5/14/2015Q115($0.64)($0.56)$1.30 million$1.90 millionViewListenView Earnings Details
3/31/2015($0.68)($0.78)ViewListenView Earnings Details
11/12/2014Q3 14($0.36)($0.55)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Immune Design Corp. (NASDAQ:IMDZ)
Current Year EPS Consensus Estimate: $-2.45 EPS
Next Year EPS Consensus Estimate: $-2.56 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.56)($0.56)($0.56)
Q2 20162($0.75)($0.63)($0.69)
Q3 20162($0.72)($0.66)($0.69)
Q4 20162($0.57)($0.54)($0.56)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Immune Design Corp. (NASDAQ:IMDZ)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Immune Design Corp. (NASDAQ:IMDZ)
Insider Ownership Percentage: 42.90%
Institutional Ownership Percentage: 53.07%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/4/2017Carlos V PayaInsiderSell3,940$5.35$21,079.00View SEC Filing  
1/4/2017Stephen R BradyEVPSell1,642$5.35$8,784.70View SEC Filing  
12/22/2016Lewis W ColemanDirectorSell10,000$6.20$62,000.00View SEC Filing  
12/16/2016Franklin M BergerDirectorSell50,000$6.55$327,500.00View SEC Filing  
9/20/2016Group L P ColumnMajor ShareholderBuy800,000$6.25$5,000,000.00View SEC Filing  
9/20/2016Lewis W ColemanDirectorBuy40,000$6.25$250,000.00View SEC Filing  
7/15/2016Stephen R BradyEVPBuy1,500$6.84$10,260.00View SEC Filing  
11/23/2015Wayne GombotzinsiderSell5,000$20.00$100,000.00View SEC Filing  
9/14/2015Wayne GombotzinsiderSell5,000$16.19$80,950.00View SEC Filing  
8/25/2015Lewis W ColemanDirectorBuy3,000$14.50$43,500.00View SEC Filing  
5/12/2015Proquest Investments Iv, L.P.Major ShareholderSell177,607$21.60$3,836,311.20View SEC Filing  
4/24/2015Proquest Investments Iv, L.P.Major ShareholderSell82,892$26.81$2,222,334.52View SEC Filing  
4/21/2015Franklin M BergerDirectorBuy25,000$26.50$662,500.00View SEC Filing  
4/21/2015Proquest Investments Iv, L.P.Major ShareholderSell45,820$26.51$1,214,688.20View SEC Filing  
4/16/2015Proquest Investments Iv, L.P.Major ShareholderSell53,914$28.23$1,521,992.22View SEC Filing  
4/7/2015Proquest Investments Iv, L.P.Major ShareholderSell7,495$26.72$200,266.40View SEC Filing  
3/25/2015Proquest Investments Iv, L.P.Major ShareholderSell18,156$27.64$501,831.84View SEC Filing  
3/23/2015Proquest Investments Iv, L.P.Major ShareholderSell44,464$27.52$1,223,649.28View SEC Filing  
3/18/2015Proquest Investments Iv, L.P.Major ShareholderSell50,309$26.09$1,312,561.81View SEC Filing  
3/12/2015Proquest Investments Iv, L.P.Major ShareholderSell129,342$24.94$3,225,789.48View SEC Filing  
3/9/2015Proquest Investments Iv, L.P.Major ShareholderSell39,446$25.45$1,003,900.70View SEC Filing  
7/29/2014Alta Partners Viii, L.P.Major ShareholderBuy299,559$12.00$3,594,708.00View SEC Filing  
7/29/2014Franklin M BergerDirectorBuy50,000$12.00$600,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Immune Design Corp. (NASDAQ:IMDZ)
DateHeadline
finance.yahoo.com logoImmune Design to Present at Upcoming Investor Conferences (NASDAQ:IMDZ)
finance.yahoo.com - February 18 at 10:57 AM
News IconImmune Design Corp. (NASDAQ:IMDZ) Losing Ground in Session - Aiken Advocate (NASDAQ:IMDZ)
aikenadvocate.com - February 13 at 11:55 PM
News IconChart Level Analysis on Shares of Immune Design Corp. (IMDZ) - Sherwood Daily (NASDAQ:IMDZ)
sherwooddaily.com - February 3 at 6:28 PM
News IconEarnings Parade Rolls On, What Are Analysts Saying About Immune Design Corp. (NASDAQ:IMDZ)? - Wall Street Beacon (NASDAQ:IMDZ)
wsbeacon.com - February 1 at 6:39 PM
News IconStock Watch: Focusing in on Immune Design Corp. (NASDAQ:IMDZ) - The Tribune (NASDAQ:IMDZ)
lakecitytribune.com - January 30 at 6:36 PM
News IconTrading Views: RSI, MA, and ADX Review for Immune Design Corp. (IMDZ) - Sherwood Daily (NASDAQ:IMDZ)
sherwooddaily.com - January 30 at 6:36 PM
News IconTrading Corner: Focusing in on Shares of Immune Design Corp. (NASDAQ:IMDZ) - Gilbert Daily (NASDAQ:IMDZ)
gilbertdaily.com - January 30 at 10:47 AM
News IconWatching Technical Positions on Immune Design Corp. (IMDZ) - Sherwood Daily (NASDAQ:IMDZ)
sherwooddaily.com - January 28 at 12:51 AM
News IconStock Review: Checking in on Share of Immune Design Corp. (NASDAQ:IMDZ) - The Tribune (NASDAQ:IMDZ)
lakecitytribune.com - January 26 at 7:32 PM
News IconTrading Views: Checking the Numbers for Immune Design Corp. (IMDZ) - Sherwood Daily (NASDAQ:IMDZ)
sherwooddaily.com - January 26 at 5:22 AM
News IconEarnings in Full Force, Analysts Take Aim at Immune Design Corp. (NASDAQ:IMDZ) - Wall Street Beacon (NASDAQ:IMDZ)
wsbeacon.com - January 26 at 5:22 AM
News IconEnlivened Volatility Spotted in Shares of Immune Design Corp. (NASDAQ:IMDZ) - Wall Street Beacon (NASDAQ:IMDZ)
wsbeacon.com - January 26 at 5:22 AM
News IconTechnicals in Focus for Immune Design Corp. (IMDZ) - Sherwood Daily (NASDAQ:IMDZ)
sherwooddaily.com - January 22 at 5:45 PM
News IconWith Profitability At The Forefront, Is This Stock a Top Pick: Immune Design Corp. (NASDAQ:IMDZ) - Wall Street Beacon (NASDAQ:IMDZ)
wsbeacon.com - January 17 at 6:24 PM
News IconInvestors Priming the Pump as Stock Reaches Most Volatile List: Immune Design Corp. (NASDAQ:IMDZ) - Wall Street Beacon (NASDAQ:IMDZ)
wsbeacon.com - January 17 at 6:24 PM
News IconStock Momentum Skidding to a Halt For Immune Design Corp. (NASDAQ:IMDZ) - Wall Street Beacon (NASDAQ:IMDZ)
wsbeacon.com - January 17 at 6:24 PM
News IconStock Mounting Higher Mid-Session: Immune Design Corp. (NASDAQ:IMDZ) - Wall Street Beacon (NASDAQ:IMDZ)
wsbeacon.com - January 12 at 11:23 PM
News IconImmune Design Corp IMDZ Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:IMDZ)
www.bioportfolio.com - January 12 at 6:22 PM
News IconStock Reaching Most Volatile List Today: Immune Design Corp. (NASDAQ:IMDZ) - Wall Street Beacon (NASDAQ:IMDZ)
wsbeacon.com - January 11 at 11:32 PM
biz.yahoo.com logoIMMUNE DESIGN CORP. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits (NASDAQ:IMDZ)
biz.yahoo.com - January 10 at 6:49 PM
News IconTo Buy Or Sell Immune Design Corp. (IMDZ) On Latest Analyst Consensus (NASDAQ:IMDZ)
larampadinapoli.com - December 30 at 6:19 PM
marketexclusive.com logoInsider Trading Activity Immune Design Corp. (NASDAQ:IMDZ) – Director Sold 10,000 shares of Stock (NASDAQ:IMDZ)
marketexclusive.com - December 28 at 5:49 PM
marketexclusive.com logoInsider Trading Activity Immune Design Corp. (NASDAQ:IMDZ) – Director Sold 10000 shares of Stock - Market Exclusive (NASDAQ:IMDZ)
marketexclusive.com - December 28 at 10:52 AM
News IconTop Stock With Upside & Growth Potential: Immune Design Corp. (NASDAQ:IMDZ) - Prospect Journal (NASDAQ:IMDZ)
prospectjournal.com - December 27 at 10:57 AM
stocksdaily.net logoCan Immune Design Corp. (NASDAQ:IMDZ) Post EPS Of $-0.57 ... - Stocks Daily (NASDAQ:IMDZ)
www.stocksdaily.net - December 23 at 11:07 PM
News IconInvestor Notebook: Focusing in on Shares of Immune Design Corp. (IMDZ) - Yankee Analysts (NASDAQ:IMDZ)
yankeeanalysts.com - December 21 at 6:46 PM
marketexclusive.com logoIMMUNE DESIGN CORP. (NASDAQ:IMDZ) Files An 8-K Departure of Directors or Certain Officers; Election of Directors ... - Market Exclusive (NASDAQ:IMDZ)
marketexclusive.com - December 21 at 9:21 AM
News IconDirector of Immune Design Corp (NASDAQ:IMDZ), Berger Franklin M, sells 50,000 shares worth $327,330 (NASDAQ:IMDZ)
empowerednews.net - December 20 at 11:58 PM
biz.yahoo.com logoIMMUNE DESIGN CORP. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:IMDZ)
biz.yahoo.com - December 16 at 6:28 PM
News IconTrading Radar: Checking Technicals for Immune Design Corp. (IMDZ) - Yankee Analysts (NASDAQ:IMDZ)
yankeeanalysts.com - December 13 at 11:24 PM
capitalcube.com logoETFs with exposure to Immune Design Corp. : December 13, 2016 (NASDAQ:IMDZ)
www.capitalcube.com - December 13 at 6:22 PM
insidermonkey.com logoIs Immune Design Corp (IMDZ) Going to Burn Investors? (NASDAQ:IMDZ)
www.insidermonkey.com - December 13 at 10:25 AM
News IconWilliams %R Check on Shares of Immune Design Corp. (IMDZ) - Yankee Analysts (NASDAQ:IMDZ)
yankeeanalysts.com - December 9 at 9:54 AM
finance.yahoo.com logoHeptares Scientists Solve Structure of CCR9 Chemokine Receptor Offering Unique Opportunity to Apply Structure-Based … (NASDAQ:IMDZ)
finance.yahoo.com - December 8 at 6:31 PM
News IconDave & Buster’s bucks casual-dining sales trends (NASDAQ:IMDZ)
nrn.com - December 8 at 6:31 PM
News IconFoolish to Trust the CDC on Vaccines (NASDAQ:IMDZ)
drsircus.com - December 8 at 6:31 PM
News IconThe 3 Best Biotech Stocks for 2017 (NASDAQ:IMDZ)
www.foxbusiness.com - December 8 at 6:31 PM
News IconUbuntu Core has the keys to IoT security (NASDAQ:IMDZ)
www.infoworld.com - December 8 at 10:34 AM
finance.yahoo.com logoSoligenix Announces Positive Long-Term Follow-up Results from its Phase 2 Clinical Trial of SGX942 for … (NASDAQ:IMDZ)
finance.yahoo.com - December 8 at 10:34 AM
News IconNon-drug approaches show promise against Alzheimer’s (NASDAQ:IMDZ)
pharmaphorum.com - December 8 at 10:34 AM
News IconHow to Open a Brand-New, Totally Old Restaurant (NASDAQ:IMDZ)
www.grubstreet.com - December 8 at 10:34 AM
News IconImmuno-oncology startup TCR2 promises to improve on CAR-T (NASDAQ:IMDZ)
www.fiercebiotech.com - December 8 at 10:34 AM
News IconNature Biotechnology (NASDAQ:IMDZ)
www.nature.com - December 8 at 10:34 AM
News IconNarrowing in on Trading Indicators for Immune Design Corp. (IMDZ) - Yankee Analysts (NASDAQ:IMDZ)
yankeeanalysts.com - December 6 at 3:39 PM
News IconDirectional Index Update on Immune Design Corp. (IMDZ) - Yankee Analysts (NASDAQ:IMDZ)
yankeeanalysts.com - December 6 at 5:38 AM
us.rd.yahoo.com logoImmune Design Provides Update from Two Discovery Platforms: DC-tropic ZVex Delivering Multiple Tumor Antigens (Conserved and Neo-Antigens) and G100 For Intratumoral Immunotherapy (NASDAQ:IMDZ)
us.rd.yahoo.com - December 5 at 10:55 AM
us.rd.yahoo.com logo8:17 am Immune Design will present G100 data at ASH 2016 (NASDAQ:IMDZ)
us.rd.yahoo.com - December 5 at 10:55 AM
News IconStock Concentration on Shares of Immune Design Corp. (IMDZ) - Yankee Analysts (NASDAQ:IMDZ)
yankeeanalysts.com - December 2 at 5:43 PM
capitalcube.com logoImmune Design Corp. :IMDZ-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016 (NASDAQ:IMDZ)
www.capitalcube.com - November 29 at 4:34 PM
capitalcube.com logoImmune Design Corp. :IMDZ-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016 (NASDAQ:IMDZ)
www.capitalcube.com - November 29 at 4:34 PM

Social

What is Immune Design Corp.'s stock symbol?

Immune Design Corp. trades on the NASDAQ under the ticker symbol "IMDZ."

Where is Immune Design Corp.'s stock going? Where will Immune Design Corp.'s stock price be in 2017?

4 analysts have issued 12 month price objectives for Immune Design Corp.'s stock. Their forecasts range from $15.00 to $15.00. On average, they anticipate Immune Design Corp.'s stock price to reach $15.00 in the next twelve months.

When will Immune Design Corp. announce their earnings?

Immune Design Corp. is scheduled to release their next quarterly earnings announcement on Wednesday, March, 8th 2017.

What are analysts saying about Immune Design Corp. stock?

Here are some recent quotes from research analysts about Immune Design Corp. stock:

  • According to Zacks Investment Research, "Immune Design’s primary candidates, CMB305 and G100, are being evaluated for solid tumor, and merkel cell carcinoma (MCC) and sarcoma, respectively. We are positive on its strategic agreements with companies like Sanofi, Roche, Merck and AstraZeneca, which not only validate its GLAAS platform, but also provide the company with funds in the form of collaboration and license revenues. However, the company is highly dependent on its collaboration partners for top-line growth. Although such collaborations boost the company’s pipeline development, dependence on other companies for revenue growth increases its vulnerability. Moreover, the company’s shares have underperformed the Medical-Drugs industry in the past one year. Loss estimates are stable ahead the company's Q4 release." (1/17/2017)

  • Wells Fargo & Company analysts commented, "We view CB1158 as option value for CALA shares and are impressed with pre-clinical data suggesting activity in checkpoint inhibitor failure." (5/11/2016)

Who owns Immune Design Corp. stock?

Immune Design Corp.'s stock is owned by a number of of institutional and retail investors. Top institutional investors include ProQuest Associates IV LLC (7.72%), Franklin Resources Inc. (2.91%), FMR LLC (1.75%), State Street Corp (0.93%), Alyeska Investment Group L.P. (0.66%) and Oxford Asset Management (0.40%). Company insiders that own Immune Design Corp. stock include Carlos V Paya, Franklin M Berger, Group L P Column, Lewis W Coleman, Proquest Investments Iv, LP, Stephen R Brady and Wayne Gombotz.

Who sold Immune Design Corp. stock? Who is selling Immune Design Corp. stock?

Immune Design Corp.'s stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Franklin Resources Inc. and FMR LLC. Company insiders that have sold Immune Design Corp. stock in the last year include Carlos V Paya, Franklin M Berger, Lewis W Coleman and Stephen R Brady.

Who bought Immune Design Corp. stock? Who is buying Immune Design Corp. stock?

Immune Design Corp.'s stock was acquired by a variety of institutional investors in the last quarter, including Oxford Asset Management, Perceptive Advisors LLC, State Street Corp and Alyeska Investment Group L.P.. Company insiders that have bought Immune Design Corp. stock in the last two years include Franklin M Berger, Group L P Column, Lewis W Coleman and Stephen R Brady.

How do I buy Immune Design Corp. stock?

Shares of Immune Design Corp. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Immune Design Corp. stock cost?

One share of Immune Design Corp. stock can currently be purchased for approximately $5.50.

Immune Design Corp. (NASDAQ:IMDZ) Chart for Monday, February, 20, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Immune Design Corp. (NASDAQ:IMDZ)

Earnings History Chart

Earnings by Quarter for Immune Design Corp. (NASDAQ:IMDZ)

Dividend History Chart

Dividend Payments by Quarter for Immune Design Corp. (NASDAQ:IMDZ)

Last Updated on 2/20/2017 by MarketBeat.com Staff